Novavax, Inc. (NASDAQ:NVAX) Director Sells $43,200.00 in Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 5,400 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares in the company, valued at $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Novavax Trading Up 3.3 %

NVAX opened at $8.85 on Friday. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The business’s fifty day simple moving average is $8.69 and its 200-day simple moving average is $11.34. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.92 and a beta of 2.07.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The firm had revenue of $84.51 million for the quarter, compared to the consensus estimate of $65.80 million. During the same period in the previous year, the company posted ($1.26) EPS. Novavax’s quarterly revenue was down 54.8% compared to the same quarter last year. On average, equities research analysts predict that Novavax, Inc. will post -1.44 EPS for the current year.

Institutional Investors Weigh In On Novavax

Institutional investors have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise boosted its position in Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,500 shares in the last quarter. Amalgamated Bank boosted its position in Novavax by 26.9% during the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 1,036 shares in the last quarter. Signaturefd LLC boosted its position in Novavax by 214.5% during the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 3,874 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC bought a new stake in Novavax during the second quarter valued at about $152,000. Institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on NVAX. B. Riley reaffirmed a “buy” rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Jefferies Financial Group cut their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Novavax has a consensus rating of “Hold” and an average target price of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.